Alcohol consumption is an established risk factor for breast cancer, with a particularly strong epidemiologic association with estrogen receptor–positive (ER+) disease. The estrogenic effects of alcohol are recognized, but the molecular connections between alcohol‑induced ER signaling and growth factor receptor pathways that promote tumor growth and progression have not been fully clarified. The study summarized here investigates how alcohol couples ER activity to receptor tyrosine kinase signaling in ER+ breast cancer cells and identifies neuregulin‑1 (NRG1) as a functional mediator linking those pathways.
The reported experiments used two common ER+ human breast cancer cell lines, MCF‑7 and T47D, under estrogen‑depleted culture conditions to assess alcohol effects in the absence of added estrogen. Endpoints included proliferation, clonogenic growth, cell‑cycle progression, migration and invasion assays, measures of ERα phosphorylation and transcriptional activity (including ERα occupancy at the endogenous TFF1/pS2 regulatory region), RTK activation, downstream kinase signaling, and gene expression of NRG1. Both pharmacologic and genetic perturbations were applied: the ER antagonist ICI 182,780 (fulvestrant) was used to inhibit ER signaling, and shRNA was used to deplete NRG1 expression.
In estrogen‑depleted conditions, alcohol exposure increased ERα phosphorylation and enhanced ER transcriptional activity in MCF‑7 and T47D cells. The authors report increased ERα occupancy at the endogenous TFF1/pS2 regulatory region, consistent with heightened ER engagement of target gene regulatory elements. These ER signaling changes accompanied alcohol‑stimulated proliferation, clonogenic growth, and progression through S phase.
Concurrently with ER activation, alcohol induced activation of the receptor tyrosine kinase ErbB3 and downstream signaling cascades, specifically Akt, ERK, and p38. This pattern indicates that alcohol exposure in ER+ breast cancer cells engages not only nuclear hormone receptor‑mediated transcription but also growth factor receptor–mediated kinase signaling networks implicated in cell survival, proliferation, and motility.
A key observation is that alcohol increased expression of neuregulin‑1 (NRG1) in both MCF‑7 and T47D cells. Pharmacologic inhibition of ER signaling with ICI 182,780 (fulvestrant) substantially attenuated alcohol‑driven induction of NRG1, blocked ErbB3/RTK activation, and reduced alcohol‑promoted cell growth. These results indicate that alcohol‑induced NRG1 expression and subsequent engagement of ErbB3/RTK signaling are strongly dependent on functional ER signaling.
Genetic depletion of NRG1 using shRNA markedly reduced alcohol‑induced phenotypes. NRG1 knockdown suppressed alcohol‑stimulated proliferation, clonogenic growth, and cell‑cycle progression. It also substantially decreased alcohol‑induced migratory and invasive behaviors. At the signaling level, NRG1 depletion attenuated ErbB3‑linked activation of Akt and ERK and concomitantly reduced ERα activation and ERE‑dependent transcriptional output. These findings demonstrate that NRG1 contributes functionally to both the growth factor receptor arm and the ER transcriptional arm of the response to alcohol.
Collectively, the data support a reciprocal signaling circuit in which alcohol‑induced ER activity promotes NRG1 expression, and NRG1‑dependent activation of ErbB3 reinforces ER activation and downstream transcriptional programs. Through this ER–NRG1–ErbB3 axis, alcohol exposure may couple estrogenic signaling to RTK‑driven proliferative and invasive phenotypes in ER+ breast cancer cells. The authors identify NRG1 as a previously unrecognized molecular link between the estrogenic activity of alcohol and growth factor receptor signaling, offering a mechanistic framework for alcohol‑associated promotion of ER+ breast cancer in these preclinical models.
This report is presented as a preprint and has not been peer reviewed; the authors explicitly note the preprint status. The summary above reflects the experimental findings and interpretations as reported in the source. Competing interests were declared as none. Funders listed include the National Institute of General Medical Sciences, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Minority Health and Health Disparities. Specific experimental details, data quantification, dose ranges of alcohol used, and full methodological descriptions are reported in the original preprint but are not reproduced in detail here.
The findings are preclinical and derived from in vitro cell line models. They suggest a mechanistic basis—an ER–NRG1–ErbB3 reciprocal signaling loop—by which alcohol can amplify proliferative and invasive behaviors in ER+ breast cancer cells. Translation of these observations to clinical risk modification, biomarker development, or therapeutic strategies would require additional validation in in vivo models and clinical studies. The identification of NRG1 as a mediator raises potential avenues for further research into whether targeting NRG1–ErbB3 signaling could mitigate alcohol‑associated tumor promotion in ER+ breast cancer, but such implications were not tested in the reported experiments.